neratinib + digoxin

**Neratinib + digoxin** is a combination of two pharmaceutical agents: neratinib, an irreversible pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor used primarily for the treatment of HER2-positive breast cancer, and digoxin, a cardiac glycoside that inhibits sodium-potassium ATPase used in the management of various heart conditions such as atrial fibrillation and heart failure[2][3][1]. Neratinib binds to and inhibits the intracellular kinase domains of HER1 (EGFR), HER2, and HER4, blocking cell signaling and proliferation[5]. Digoxin acts by increasing myocardial contractility but has a narrow therapeutic index[3]. When co-administered, neratinib can increase digoxin systemic exposure by inhibiting P-glycoprotein (P-gp) transporters, resulting in increased digoxin plasma concentrations and potential risk for digoxin toxicity[1][3][6]. This interaction is clinically significant and patients treated with this combination should be carefully monitored.

Brand names

Nerlynx (neratinib)Lanoxin (digoxin)

Other names

neratinib + digoxin